Comparative Pharmacology
Head-to-head clinical analysis: NALFON versus ORUDIS KT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALFON versus ORUDIS KT.
NALFON vs ORUDIS KT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
None Documented
None Documented
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)